SCOPUS 정보 검색 플랫폼

AIDS

Volumn 19, Issue 17, 2005, Pages 2054-2055

Atazanavir/ritonavir versus lopinavir/ritonavir: Equivalent or different efficacy profiles? [8]

(1) Hill, Andrew a

a UNIVERSITY OF LIVERPOOL (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; RITONAVIR; TENOFOVIR; ZIDOVUDINE;

CLINICAL TRIAL; DATA ANALYSIS; DISEASE CLASSIFICATION; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PRIORITY JOURNAL; RNA ANALYSIS;

EID: 27944469565 PISSN: 02699370 EISSN: None Source Type: Journal
DOI: 10.1097/01.aids.0000194137.73876.d5 Document Type: Letter

Times cited : (3)

References (5)

1
- 22444439664
- Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures
- Johnson M, Grinszstejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005; 19:685-694.
- (2005) AIDS , vol.19 , pp. 685-694
- Johnson, M.¹ Grinszstejn, B.² Rodriguez, C.³ Coco, J.⁴ DeJesus, E.⁵ Lazzarin, A.⁶

2
- 0042454476
- US Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Clinical Medical, October
- Food and Drug Administration. Guidance for industry: antiretroviral drugs using plasma HIV RNA measurements - clinical considerations for accelerated and traditional approval. US Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Clinical Medical, October 2002. Available at: http://www.fda.gov/cder/guidance/index.htm. Accessed: April 2005.
- (2002) Guidance for Industry: Antiretroviral Drugs Using Plasma HIV RNA Measurements - Clinical Considerations for Accelerated and Traditional Approval

3
- 2342537759
- Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection
- Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med (US) 2004; 350:1850-1861.
- (2004) N Engl J Med (US) , vol.350 , pp. 1850-1861
- Gulick, R.M.¹ Ribaudo, H.J.² Shikuma, C.M.³ Lustgarten, S.⁴ Squires, K.E.⁵ Meyer, W.A.⁶

4
- 14944368689
- The combination of tenofovir DF (TDF), emtricitabine (FTC) and efavirenz (EFV) has significantly greater response vs fixed dose zidovudine/lamivudine (CBV) and EFV in antiretroviral naive patients: A 24 week preliminary analysis
- Washington, USA, October. Abstract 3778
- Gazzard B, DeJesus E, Campo R, Jemsek J, Gallant J, Arribas J. The combination of tenofovir DF (TDF), emtricitabine (FTC) and efavirenz (EFV) has significantly greater response vs fixed dose zidovudine/lamivudine (CBV) and EFV in antiretroviral naive patients: a 24 week preliminary analysis. In: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, USA, October 2004 (Abstract 3778).
- (2004) 44th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Gazzard, B.¹ DeJesus, E.² Campo, R.³ Jemsek, J.⁴ Gallant, J.⁵ Arribas, J.⁶

5
- 27944488930
- Enfuvirtide (Fuzeon). Nutley, NJ, USA: Roche Pharmaceuticals/Trimeris, revised October
- Enfuvirtide (Fuzeon). US prescribing information. Nutley, NJ, USA: Roche Pharmaceuticals/Trimeris, revised October 2004.
- (2004) US Prescribing Information

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.